Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Neurology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 9409357
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Insulin-like growth factor-1 receptors in human spinal cord: changes in amyotrophic lateral sclerosis

  2005cited by this paper
• Distribution and levels of insulin-like growth factor (IGF-I and IGF-II) and insulin receptor binding sites in the spinal cords of amyotrophic lateral sclerosis (ALS) patients.

  1996cited by this paper
• Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II.

  1996cited by this paper
• Relationship of the Tufts Quantitative Neuromuscular Exam (TQNE) and the Sickness Impact Profile (SIP) in measuring progression of ALS

  1996cited by this paper
• Molecular approaches to amyotrophic lateral sclerosis.

  1995cited by this paper
• Amyotrophic lateral sclerosis: Recent insights from genetics and transgenic mice

  1995cited by this paper
• Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction.

  1995cited by this paper
• Amyotrophic lateral sclerosis: human challenge for neuroscience.

  1995cited by this paper
• A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group.

  1994cited by this paper
• Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis.

  1993cited by this paper
• Superoxide Dismutase Activity, Oxidative Damage, and Mitochondrial Energy Metabolism in Familial and Sporadic Amyotrophic Lateral Sclerosis

  1993cited by this paper
• Onset, natural history and outcome in idiopathic adult motor neuron disease.

  1993cited by this paper
• Activity‐Sensitive Signaling by Muscle‐Derived Insulin‐like Growth Factors in the Developing and Regenerating Neuromuscular System

  1993cited by this paper
• Insulin-like growth factor-I: potential for treatment of motor neuronal disorders.

  1993cited by this paper
• The Potential of Insulin‐like Growth Factor‐I as a Therapeutic for the Treatment of Neuromuscular Disorders

  1993cited by this paper
• Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis.

  1992cited by this paper
• Motor neuron disease (amyotrophic lateral sclerosis).

  1991cited by this paper
• Recombinant human insulin-like growth factor I: effects in normal subjects and implications for use in patients.

  1991cited by this paper
• Nerve sprouting in innervated adult skeletal muscle induced by exposure to elevated levels of insulin-like growth factors

  1990cited by this paper
• A double-blind study of the effectiveness of cyclosporine in amyotrophic lateral sclerosis.

  1988cited by this paper
• A rating scale for amyotrophic lateral sclerosis: Description and preliminary experience

  1987cited by this paper
• The Sickness Impact Profile: Development and Final Revision of a Health Status Measure

  1981cited by this paper

• Type 2 diabetes mellitus, antidiabetics, and the risk of amyotrophic lateral sclerosis

  2025cites this paper
• Exploring amyotrophic lateral sclerosis patients’ experiences of psychological distress during the disease course in China: a qualitative study

  2024cites this paper
• GHRH and its analogues in central nervous system diseases

  2024cites this paper
• Learning From the Exception and Not the Rule: Genetic Associations With an Amyotrophic Lateral Sclerosis Reversal Phenotype.

  2024cites this paper
• Regeneration mechanisms and therapeutic strategies for neuromuscular junctions in aging and diseases

  2024cites this paper
• The signaling landscape of insulin-like growth factor 1

  2024cites this paper
• Genetic Associations With an Amyotrophic Lateral Sclerosis Reversal Phenotype

  2024cites this paper
• Effect of ultrasound-mediated blood-spinal cord barrier opening on survival and motor function in females in an amyotrophic lateral sclerosis mouse model

  2024cites this paper
• The neurobiology of insulin-like growth factor I: From neuroprotection to modulation of brain states

  2023cites this paper
• Therapeutic Effects of Combination of Nebivolol and Donepezil: Targeting Multifactorial Mechanisms in ALS

  2023cites this paper
• Therapeutic targeting of ALS pathways: Refocusing an incomplete picture

  2023cites this paper
• Quality of Life of Amyotrophic Lateral Sclerosis Patients in Iran

  2023cites this paper
• Exercise Promotes Tissue Regeneration: Mechanisms Involved and Therapeutic Scope

  2023cites this paper
• Neurotrophic Factors as Regenerative Therapy for Neurodegenerative Diseases: Current Status, Challenges and Future Perspectives

  2023cites this paper
• Chloroplast transformation for bioencapsulation and oral delivery using the immunoglobulin G fragment crystallizable (Fc) domain

  2023cites this paper
• Chloroplast transformation for bioencapsulation and oral delivery using the immunoglobulin G fragment crystallizable (Fc) domain

  2023cites this paper
• Growth factors and molecular-driven plasticity in neurological systems.

  2023cites this paper
• Insulin-like Growth Factor-1 (IGF-1) Related Drugs in Pain Management

  2023cites this paper
• Emerging Roles of the Neurotrophic Peptides IGF-1 and PACAP in Amyotrophic Lateral Sclerosis.

  2022cites this paper
• Enhanced insulin signalling ameliorates C9orf72 hexanucleotide repeat expansion toxicity in Drosophila

  2021cites this paper
• Dysregulation of IGF-1/GLP-1 signaling in the progression of ALS: potential target activators and influences on neurological dysfunctions

  2021cites this paper
• Motor Neuron Diseases and Neuroprotective Peptides: A Closer Look to Neurons

  2021cites this paper
• Influence of IGF-I serum concentration on muscular regeneration capacity in patients with sarcopenia

  2021cites this paper
• The links between diabetes mellitus and amyotrophic lateral sclerosis

  2021cites this paper
• Focal and dose-dependent neuroprotection in ALS mice following AAV2-neurturin delivery.

  2020cites this paper
• The clinical trial landscape in amyotrophic lateral sclerosis—Past, present, and future

  2020cites this paper
• Enhancing peripheral nerve regeneration with neurotrophic factors and bioengineered scaffolds: A basic science and clinical perspective

  2020cites this paper
• Insulin-like growth factor 1 signaling in motor neuron and polyglutamine diseases: From molecular pathogenesis to therapeutic perspectives.

  2020cites this paper
• Riluzole

  2020cites this paper
• Glial Cells—The Strategic Targets in Amyotrophic Lateral Sclerosis Treatment

  2020cites this paper
• What skeletal muscle has to say in amyotrophic lateral sclerosis: Implications for therapy

  2020cites this paper
• Past and Future of Neurotrophic Growth Factors Therapies in ALS: From Single Neurotrophic Growth Factor to Stem Cells and Human Platelet Lysates

  2019cites this paper
• Safety, Tolerability, and Pharmacodynamics of Intrathecal Injection of Recombinant Human HGF (KP‐100) in Subjects With Amyotrophic Lateral Sclerosis: A Phase I Trial

  2018cites this paper
• Increased motor neuron resilience by small molecule compounds that regulate IGF-II expression.

  2018cites this paper
• Growth Hormone-Releasing Hormone Modulation of Neuronal Exosome Biomarkers in Mild Cognitive Impairment

  2018cites this paper
• Systemic administration of scAAV9-IGF1 extends survival in SOD1G93A ALS mice via inhibiting p38 MAPK and the JNK-mediated apoptosis pathway.

  2018cites this paper
• Insulin-like growth factor 1 in diabetic neuropathy and amyotrophic lateral sclerosis.

  2017cites this paper
• Motoneuron Disease: Clinical.

  2017cites this paper
• Clinical tests of neurotrophic factors for human neurodegenerative diseases, part 1: Where have we been and what have we learned?

  2017cites this paper
• Amyotrophic lateral sclerosis disease modifying therapeutics: a cell biological perspective

  2017cites this paper
• Clinical tests of neurotrophic factors for human neurodegenerative diseases, part 2: Where do we stand and where must we go next?

  2017cites this paper
• Gene Therapy for Amyotrophic Lateral Sclerosis

  2017cites this paper
• Nocebo in motor neuron disease: systematic review and meta-analysis of placebo-controlled clinical trials

  2017cites this paper
• ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment?

  2017influential citation
• Neurotrophic and Neuroregenerative Effects of GH/IGF1

  2017cites this paper
• Economic Studies in Motor Neurone Disease: A Systematic Methodological Review

  2017cites this paper
• α CAR IGF‐1 vector targeting of motor neurons ameliorates disease progression in ALS mice

  2016cites this paper
• The therapeutic potential of insulin-like growth factor-1 in central nervous system disorders.

  2016cites this paper
• Towards Clinical Application of Neurotrophic Factors to the Auditory Nerve; Assessment of Safety and Efficacy by a Systematic Review of Neurotrophic Treatments in Humans

  2016cites this paper
• Intramuscular Delivery of scAAV9-hIGF1 Prolongs Survival in the hSOD1G93A ALS Mouse Model via Upregulation of D-Amino Acid Oxidase

  2016cites this paper
• Differential neuronal vulnerability identifies IGF-2 as a protective factor in ALS

  2016cites this paper
• Therapeutic progress in amyotrophic lateral sclerosis-beginning to learning.

  2016cites this paper
• A retrospective review of the progress in amyotrophic lateral sclerosis drug discovery over the last decade and a look at the latest strategies

  2015cites this paper
• Gene expression profiling for human iPS-derived motor neurons from sporadic ALS patients reveals a strong association between mitochondrial functions and neurodegeneration

  2015cites this paper
• Autocrine Production of IGF‐I Increases Stem Cell‐Mediated Neuroprotection

  2015cites this paper
• Amyotrophic lateral sclerosis: Current perspectives from basic research to the clinic

  2015cites this paper
• Amyotrophic lateral sclerosis: clinical perspectives

  2015cites this paper
• ABC transporter-driven pharmacoresistance in Amyotrophic Lateral Sclerosis.

  2015cites this paper
• Genetic heterogeneity of amyotrophic lateral sclerosis: Implications for clinical practice and research

  2014cites this paper
• Moving forward in clinical trials for ALS: motor neurons lead the way please.

  2014cites this paper
• Trophic Factor Production by Glial Cells in the Treatment of Amyotrophic Lateral Sclerosis

  2014cites this paper
• Optimizing IGF-I for skeletal muscle therapeutics.

  2014cites this paper
• Understanding ALS: new therapeutic approaches

  2013cites this paper
• Study of Cyclophilin A Function in Models of Amyotrophic Lateral Sclerosis

  2013cites this paper
• IGF-I increases markers of osteoblastic activity and reduces bone resorption via osteoprotegerin and RANK-ligand

  2013cites this paper
• Insulin-like growth factor and the etiology of autism.

  2013cites this paper
• Calcium-dependent protein folding in amyotrophic lateral sclerosis.

  2013cites this paper
• Intermittent hypoxia and stem cell implants preserve breathing capacity in a rodent model of amyotrophic lateral sclerosis.

  2013cites this paper
• [Amyotrophic lateral sclerosis: update on etiological treatment].

  2013cites this paper
• Growth hormone secretion is correlated with neuromuscular innervation rather than motor neuron number in early-symptomatic male amyotrophic lateral sclerosis mice.

  2013cites this paper
• Tissue Engineering Approaches for Motor Neuron Pathway Regeneration

  2012cites this paper
• Treatment for cramps in amyotrophic lateral sclerosis/motor neuron disease.

  2012cites this paper
• Therapeutic potential of PEGylated insulin-like growth factor I for skeletal muscle disease evaluated in two murine models of muscular dystrophy.

  2012cites this paper
• Impairments to the GH-IGF-I axis in hSOD1G93A mice give insight into possible mechanisms of GH dysregulation in patients with amyotrophic lateral sclerosis.

  2012cites this paper
• Somatomedin-1 (Recombinant Insulin-Like Growth Factor-1)

  2012cites this paper
• Delayed administration of VEGF rescues spinal motor neurons from death with a short effective time frame in excitotoxic experimental models in vivo

  2012cites this paper
• Therapeutic Potential of Neurotrophic Factors in Neurodegenerative Diseases

  2012cites this paper
• Insulinlike Growth Factor (IGF)-1 Administration Ameliorates Disease Manifestations in a Mouse Model of Spinal and Bulbar Muscular Atrophy

  2012cites this paper
• Intranasal administration: a potential solution for cross-BBB delivering neurotrophic factors.

  2012cites this paper
• Impaired Expression of Insulin-Like Growth Factor-1 System in Skeletal Muscle of Amyotrophic Lateral Sclerosis Patients

  2012cites this paper
• [The role of neurotrophic factors in regeneration of the nervous system].

  2012cites this paper
• Association of Skin with the Pathogenesis and Treatment of Neurodegenerative Amyloidosis

  2012cites this paper
• Current and prospective disease-modifying therapies for amyotrophic lateral sclerosis

  2012cites this paper
• Human conditions of insulin-like growth factor-I (IGF-I) deficiency

  2012cites this paper
• Neuroprotection for amyotrophic lateral sclerosis: role of stem cells, growth factors, and gene therapy.

  2012cites this paper
• Insulin-like growth factors in the peripheral nervous system.

  2012cites this paper
• Stem Cell Application for Amyotrophic Lateral Sclerosis: Growth Factor Delivery and Cell Therapy

  2012cites this paper
• Cost Effectiveness of Treatments for Amyotrophic Lateral Sclerosis

  2012cites this paper
• PROGNOSTIC CATEGORIES FOR AMYOTROPHIC LATERAL SCLEROSIS

  2012cites this paper
• Functional improvement in mouse models of familial amyotrophic lateral sclerosis by PEGylated insulin-like growth factor I treatment depends on disease severity

  2012cites this paper
• Recombinant human insulin-like growth factor I (rhIGF-I) for the treatment of amyotrophic lateral sclerosis/motor neuron disease.

  2012cites this paper
• Amyotrophic Lateral Sclerosis Progress and Prospects for Treatment

  2012cites this paper
• Emerging targets and treatments in amyotrophic lateral sclerosis.

  2011cites this paper
• Restorative effect of intracerebroventricular insulin-like growth factor-I gene therapy on motor performance in aging rats.

  2011cites this paper
• Therapeutic effects of PEGylated insulin-like growth factor I in the pmn mouse model of motoneuron disease.

  2011cites this paper
• Amyotrophic lateral sclerosis: from research to therapeutic attempts and therapeutic perspectives.

  2011cites this paper
• Motor neuron trophic factors: therapeutic use in ALS?

  2011cites this paper
• Stem cell technology for the study and treatment of motor neuron diseases.

  2011cites this paper
• New therapeutic targets for amyotrophic lateral sclerosis

  2011cites this paper
• Emerging drugs for amyotrophic lateral sclerosis

  2011cites this paper